Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Next Previous
Trial Profile

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SL 701 (Primary) ; Bevacizumab; Granulocyte macrophage colony stimulating factor; Imiquimod; Poly ICLC
  • Indications Glioblastoma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemline Therapeutics

    • Most Recent Events

    • 15 Mar 2019 According to a Stemline Therapeutics media release, the company expect to provide further updates on this study later this year.
    • 02 Jan 2019 According to a Stemline Therapeutics media release, recent data from this study were presented at the Society for Neuro-Oncology (SNO) annual conference.
    • 16 Nov 2018 According to a Stemline Therapeutics media release, data from this trial will be presented at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO) being held November 15-18, 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top